Sol-Gel Technologies Ltd. Ordinary Shares earnings per share and revenue
On Nov 20, 2025, SLGL reported earnings of -2.13 USD per share (EPS) for Q3 25, beating the estimate of -2.13 USD, resulting in a 0.08% surprise. Revenue reached 400.00 thousand, compared to an expected 306.00 thousand, with a 30.72% difference. The market reacted with a -0.80% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of 0.39 USD, with revenue projected to reach 6.63 million USD, implying an decrease of -118.31% EPS, and increase of 1557.50% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Teva Pharmaceutical Industries Limited - ADR
Report Date
Jan 28, 2026 For Q4 25
Estimate
$0.69
Actual
$0.96
Surprise
+38.55%
Dr. Reddy's Laboratories Limited - ADR
Report Date
Jan 21, 2026 For Q3 26
Estimate
$13.86
Actual
$14.65
Surprise
+5.66%
FAQ
What were Sol-Gel Technologies Ltd. Ordinary Shares's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Sol-Gel Technologies Ltd. Ordinary Shares reported EPS of -$2.13, missing estimates by 0.08%, and revenue of $400.00K, 30.72% above expectations.
How did the market react to Sol-Gel Technologies Ltd. Ordinary Shares's Q3 2025 earnings?
The stock price moved down -0.8%, changed from $36.04 before the earnings release to $35.75 the day after.
When is Sol-Gel Technologies Ltd. Ordinary Shares expected to report next?
The next earning report is scheduled for Mar 23, 2026.
What are the forecasts for Sol-Gel Technologies Ltd. Ordinary Shares's next earnings report?
Based on 3
analysts, Sol-Gel Technologies Ltd. Ordinary Shares is expected to report EPS of $0.39 and revenue of $6.63M for Q4 2025.